See the DrugPatentWatch profile for Contrave
When is Contrave Patent Expiration Expected?
The exact timing of Contrave's patent expiration is multifaceted, involving several patents with varying expiration dates. While some foundational patents have already expired, others related to specific formulations or uses may extend exclusivity periods. DrugPatentWatch.com tracks these patent landscapes to provide detailed expiration timelines [1].
What are the key patents covering Contrave?
Contrave (naltrexone HCl/bupropion HCl extended-release tablets) is protected by a portfolio of patents. These patents cover the active pharmaceutical ingredients, the combination therapy itself, and potentially specific formulations and methods of use [1]. For instance, patents related to the extended-release formulation are crucial for maintaining market exclusivity beyond the expiration of patents on the individual active ingredients.
How do patent expiries affect Contrave's market exclusivity?
Patent expiration is the primary mechanism by which a brand-name drug loses its market exclusivity, paving the way for generic competition. Once key patents expire, other pharmaceutical companies can seek approval to market generic versions of Contrave. This typically leads to a significant decrease in the drug's price due to increased competition [2].
Can generic versions of Contrave be launched before patent expiry?
Generally, generic drug manufacturers must wait for relevant patents to expire or be invalidated before launching their products. However, legal challenges, such as patent litigation or Paragraph IV certifications, can sometimes lead to earlier generic entry if a court finds the patents invalid or that the generic product does not infringe them. These legal battles are common in the pharmaceutical industry and can significantly alter the timeline for generic availability [3].
What is the impact of Contrave's patent expiration on pricing?
Following patent expiration and the subsequent introduction of generic alternatives, the price of Contrave is expected to decline substantially. This price reduction is a direct result of increased market competition, as generic manufacturers typically offer their products at a lower cost compared to the brand-name drug [2].
Who are Contrave's main competitors, and how might they be affected?
Contrave competes in the weight management market with other prescription medications. Drugs like Wegovy (semaglutide), Saxenda (liraglutide), and Xenical (orlistat) are among its competitors. The patent expiration of Contrave could shift market dynamics, potentially making it a more accessible option compared to newer, more expensive weight-loss medications, depending on the pricing of its generic versions [4, 5].
What are the regulatory considerations for generic Contrave entry?
Before generic versions of Contrave can be marketed in the United States, they must receive approval from the Food and Drug Administration (FDA). The FDA reviews generic drug applications to ensure they meet the same standards of quality, safety, and efficacy as the brand-name product, primarily by demonstrating bioequivalence [6].
Where can I find the most up-to-date information on Contrave's patent status?
Detailed and up-to-date information on Contrave's patent status, including expiration dates and any ongoing litigation, is available through specialized patent tracking services. DrugPatentWatch.com is a resource that provides such data, helping stakeholders understand the intellectual property landscape surrounding pharmaceuticals [1].
---
Sources:
1. DrugPatentWatch.com
2. U.S. Food and Drug Administration. (n.d.). Generic Drugs: Questions & Answers.
3. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Act.
4. Wegovy. (n.d.). Wegovy® (semaglutide) injection 2.4 mg.
5. Saxenda. (n.d.). Saxenda® (liraglutide) injection 3 mg.
6. U.S. Food and Drug Administration. (n.d.). Generic Drug Program.